SAN DIEGO—Pre-dialysis transplant recipients with a high level of kidney function do not appear to benefit from their transplant more than pre-dialysis recipients with a low level of kidney function, data show.
It may be possible to detect acute allograft rejection in kidney transplant patients by urinary proteome analysis, according to a new German study that was presented at ASN’s Renal Week 2009.
Among pediatric renal transplant recipients, increased age and having a very high or very low BMI, steroid use at the time of hospital discharge are three independent factors associated with an increased risk of new onset diabetes, according to new data presented at ASN’s Renal Week 2009.
An intensified-dosing regimen of enteric-coated mycophenolate sodium in combination with basiliximab and standard doses of cyclosporine may result in a lower rate of rejection without compromising safety and tolerability, according to new data presented at ASN’s Renal Week 2009.
Treatment of stable renal transplant recipients with a regimen of high-dose folic acid and vitamins B6 and B12 lowers total homocysteine levels better than a low-dose multivitamin containing no folic acid.
Switching to sirolimus from a calcineurin inhibitor may reduce the high risk of skin cancer after kidney transplantation, according to a new multi-centered trial conducted in Australia, New Zealand and the United States that was presented at ASN’s Renal Week 2009.
Active surveillance for BK virus with prompt reduction in immunosuppression therapy may help minimize graft loss due to BK nephropathy, according to researchers who presented their study at ASN’s Renal Week 2009.
SAN DIEGO—Following renal transplant failure, patients starting peritoneal dialysis (PD) have better survival in the first year than patients starting on hemodialysis (HD), but the survival advantage lessens with time, British resesarchers reported at the American Society of Nephrology’s Renal Week conference.
Contrary to previous studies, lupus patients who receive kidney transplants rarely develop lupus nephritis in their new allograft, according to a study presented at ASN’s Renal Week conference.
Despite the fact that cardiovascular diseases are the leading cause of death in kidney transplant patients, overall utilization of cardioprotective drugs—such as antihypertensive agents and statins—is low in this high-risk population, Hungarian researchers reported at ASN’s Renal Week 2009.
Please login or register first to view this content.
